Recognition underscores Keysight's market leadership, customer-centric innovation, and pioneering role in accelerating 6G technology validation through AI, digital twin testing, and spectrum exploration
SAN ANTONIO,...
Recognition underscores Keysight's market leadership, customer-centric innovation, and pioneering role in accelerating 6G technology validation through AI, digital twin testing, and spectrum exploration
SAN ANTONIO,...
Recognition underscores Keysight's market leadership, customer-centric innovation, and pioneering role in accelerating 6G technology validation through AI, digital twin testing, and spectrum exploration
SAN ANTONIO,...
Recognition underscores Keysight's market leadership, customer-centric innovation, and pioneering role in accelerating 6G technology validation through AI, digital twin testing, and spectrum exploration
SAN ANTONIO,...
SKYX Pre-Announces Record Second Quarter 2025 Revenues of $23.1 Million Compared to First Quarter Revenues of $20.1 Million, as it Continues to Grow Market
KIRKLAND, QC, July 31, 2025 /CNW/ - Laurentide Controls is pleased to announce the expansion of its partnership with Danfoss, now officially acting as a...
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025.
VedTechBio enhances RxAgentAI platform; teams with US-based AlphaMeld to cut drug discovery time and co-develop therapies for rare and metabolic diseases.
The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...
The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.
WATERLOO, ON, July 30, 2025 /PRNewswire/ -- OpenText™ (NASDAQ: OTEX), (TSX: OTEX), the leading information management company, and TELUS, a world-leading communications technology company, today...
AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Round Barn Labs (RBL), a leader in affiliate and influencer marketing for tech brands like Future Fitness, Atlassian, Grammarly, Wyze, Remote, and Meta Quest, unveils TruPartner Score™—a proprietary algorithm that empowers brands to build high-performing, trusted partnerships.